Andrew Kotila's Contact Details

Andrew Kotila's Company Details

Quantapore Inc

, , • 11 - 50 Employees
Biotechnology

Quantapore's novel, high throughput, massively parallel sequencer will allow rapid, affordable and sensitive sequencing of entire genomes. This desktop system will address the need for efficient sequencing. Revenues will be garnered by seeding units into customer facilities, and then by the sale of consumable cartridges; providing rapid growth as the installed base and customer utilization increases. Quantapore's novel, proprietary DNA sequencing technology is based on an optically labeled nanopore which interacts via energy transfer with a labeled nucleic acid sample. The quantum-optic interaction between the nanopore and the DNA allows for single molecule nucleic acid sequencing at an unprecedented speed and cost. The global market for genetics/genomics is estimated at $5.8 billion, while the DNA sequencing segment is estimated at ~$2.7 billion. The sequencing market will approximately double by 2015 with equipment and consumable sales representing around 2/3 of the total market. However, the un-tapped potential of this market is currently estimated at about $30 billion, leaving a large unmet demand for sequencing.